Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study.

paythelady.612 shared this article with you from Inoreader Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study. Μέσω pubmed: "world j clin cases"... Related Articles Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study. World J Clin Cases. 2021 Jan 06;9(1):71-80 Authors: Lu YL, Chen ST, Ho TY, Chan WH, Wong RJ, Hsueh C, Lin SF Abstract BACKGROUND: A proportion of lung cancers show sodium/iodide symporter (NIS) expression. Lung cancers with NIS expression may uptake radioiodine (RAI) and show RAI-avid lesions on RAI scan for differentiated thyroid cancer (DTC) surveillance. AIM: To investigate the possibility of RAI uptake by lung cancer in a cohort with thyroid cancer. METHODS: RAI-avid lung cancers were analyzed using a prospectively maintained database of patients with thyroid cancer who were registered at a medical center between December 1, 1976 and May 28, 2018. NIS expression in lung cancer was assessed using immunohistochemical staining. RESULTS: Of the 5000 patients with thyroid cancer from the studied dataset, 4602 had DTC. During follow-up, 33 patients developed primary lung cancer. Of these patients, nine received an iodine-131 (131I) scan within 1 year before the diagnosis of lung cancer. One of these nine lung cancers was RAI-avid. NIS expression was evaluated, and three of the eight available lung cancers revealed NIS expression. The proportions of lung cancer cells with NIS expression were 60%, 15%, and 10%. The RAI-avid lung cancer had the highest level of expression (60%). The RAI-avid lung cancer had a spiculated border upon single-photon emission computed tomography/computed tomography, which led to an accurate diagnosis. CONCLUSION: A proportion of lung cancer demonstrates NIS expression and is RAI-avid. Clinicians should be aware of this possibility in the interpretation of RAI scintigraphy. PMID: 33511173 [PubMed] View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.